Annexon, Inc.: directors' dealings · United States · SEC (Form 4)

About Annexon, Inc.

Annexon, Inc. is a U.S.-listed biopharmaceutical company trading on the NASDAQ under the ticker ANNX. The company is headquartered in Brisbane, California, United States, and traces its origins to the early 2010s, with its founding commonly associated with 2011. For investors, the key takeaway is that Annexon remains a development-stage biotech: it does not yet have an approved commercial product, and its valuation is driven primarily by clinical execution, regulatory milestones, and the eventual market opportunity for its pipeline. Annexon’s business is built around a highly focused scientific thesis: selectively blocking the classical complement pathway, especially the C1q protein, to reduce inflammatory and neurodegenerative damage. This strategy sits at the intersection of immunology, neurology, and ophthalmology. The company positions itself as a specialist in complement-mediated disease biology, aiming to address serious disorders affecting the body, brain, and eye. Its lead programs include tanruprubart (ANX005) for Guillain-Barré syndrome, vonaprument (ANX007) for geographic atrophy, and ANX1502, an oral small-molecule complement inhibitor being developed for autoimmune indications. Annexon has also highlighted additional pipeline assets over time, but these three programs are the main value drivers currently referenced in company communications. From a competitive standpoint, Annexon is differentiated by its narrow but deep focus on the classical complement cascade. That specialization gives the company a potentially attractive first-in-class or category-leading profile if the data continue to support its mechanism of action. At the same time, it also means the investment case is concentrated: a relatively small number of late-stage assets carry most of the company’s prospective value. As with most clinical-stage biopharma names, the upside can be significant, but the risk profile is inherently binary and sensitive to trial outcomes, FDA interactions, and financing conditions. Recent corporate and clinical updates have centered on portfolio progress across ANX005, ANX007, and ANX1502, alongside regulatory engagement and new financing activity. In 2025 and 2026, Annexon emphasized progress in late-stage development and reported that its funding runway extends into the second half of 2027, based on recent company disclosures. For investors in France, Belgium, and Switzerland, Annexon should be viewed as a specialized U.S. NASDAQ biotech with a focused immunology platform, a concentrated pipeline, and several near-term catalysts that could materially re-rate the shares in either direction.